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Abstract
Background: The only available diagnostic method for East African trypanosomiasis is light microscopy of blood samples. A
simple immunodiagnostic would greatly aid trypanosomiasis control.
Methodology and Principal Findings: To find trypanosome proteins that are specifically recognised by sera from human
sleeping sickness patients, we have screened the Trypanosoma brucei brucei proteome by Western blotting. Using cytosolic,
cytoskeletal and glycosomal fractions, we found that the vast majority of abundant trypanosome proteins is not specifically
recognised by patient sera. We identified phosphoglycerate kinase (PGKC), heat shock protein (HSP70), and histones H2B
and H3 as possible candidate diagnostic antigens. These proteins, plus paraflagellar rod protein 1, rhodesain (a cysteine
protease), and an extracellular fragment of the Trypanosoma brucei nucleoside transporter TbNT10, were expressed in E. coli
and tested for reactivity with patient and control sera. Only TbHSP70 was preferentially recognized by patient sera, but the
sensitivity and specificity were insufficient for use of TbHSP70 alone as a diagnostic. Immunoprecipitation using a native
protein extract revealed no specifically reacting proteins.
Conclusions: No abundant T. brucei soluble, glycosomal or cytoskeletal protein is likely to be useful in diagnosis. To find
useful diagnostic antigens it will therefore be necessary to use more sophisticated proteomic methods, or to test a very
large panel of candidate proteins.
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Introduction
Human African trypanosomiasis is transmitted by Tsetse flies
and occurs in a broad band from south of the Sahara to
Zimbabwe. It occurs in two major forms, caused by Trypanosoma
brucei gambiense (T. b. gambiense) in West and Central Africa and
Trypanosoma brucei rhodesiense (T. b. rhodesiense) in East and Southern
Africa. The initial symptoms are very non-specific, so the disease
may not be diagnosed until the parasites have penetrated the
brain, at which point treatment becomes both difficult and
dangerous [1,2]. A sustained control programme is required if new
trypanosomiasis epidemics are to be avoided [3]. For primary
screening, a low-cost, simple and rapid diagnosis method with high
sensitivity is required: microscopic confirmation and a DNA-based
subspecies determination could then be restricted to positive cases.
African trypanosomes are coated by Variant Surface Glyco-
protein (VSG), and have many VSG genes and pseudogenes which
are sequentially expressed during infection. Although there are
enormous variations in repertoire between isolates, most T. b.
gambiense isolates possess and express at least one of three particular
VSG genes. This enabled the development, for T. b. gambiense
infection, of the rapid Card Agglutination Test for Trypanosomi-
asis (CATT); this relies on the presence of antibodies to those
VSGs in patients [4]. Since all available sleeping sickness
treatments have severe side-effects, this test is always followed by
microscopic examination for live parasites [4,5]. Microscopy of
thick films has low sensitivity (10,000 parasites per ml) [4] and
scanning a slide can take 10 minutes; use of haematocrit tubes
increases the sensitivity, but is more time consuming [4], so
microscopy is not really practical as a large-scale screening
method. The CATT test is also not 100% sensitive: false negatives
arise because some T. b. gambiense do not express the relevant
VSGs. Worse, no shared VSGs have been found for T. b.
rhodesiense, so there is no field-adapted screening test for East
African trypanosomiasis. DNA amplification methods [6][7] are
highly sensitive for detection of trypanosomes, and easily capable
of distinguishing between species and subspecies. The most
sensitive method to date, loop-mediated isothermal amplification
(LAMP) [7], relies on amplification of a multicopy transposon-like
sequence for detection of T. brucei, with more specific primers for
subspecies determination. There is however no immediate
prospect of the use of amplification methods for surveillance of
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consuming, and require too much training for implementing
personnel.
The simplest and cheapest rapid tests for T. b. rhodesiense are
likely – like the CATT - to rely on antibodies to trypanosome
antigens in sera. The ideal candidate for development of a
serodiagnostic tool should be an immunogenic protein that is
consistently expressed by the bloodstream-form trypanosomes. All
trypanosome proteins are potential candidates, since they are all
released into the circulation: trypanosomes are regularly lysed by
the host immune system as they undergo antigenic variation.
Correspondingly, HAT sera contain antibodies which react with
trypanosome proteins other than the VSG. Indeed, a preparation
of formalin-fixed, ethanol-treated and stained insect-stage T. brucei
(which lack VSG) was used to create an agglutination test which
was reported to have 98% sensitivity and 96% specificity [8]. The
ethanol treatment might expose internal proteins. However, this
result seems not to have been followed up. An ELISA assay for the
related parasite Trypanosoma evansi, based on a soluble protein
extract, also gave promising results [9] although sensitivity was less
than 90% [10]. So far, however, the antigens involved have not
been characterized.
Another possibility is to test candidate pure proteins [11]. Two
T. brucei proteins that were identified by expression library
screening, using serum from infected cattle [12], turned out to
be cytoskeletal proteins that were also recognised by sera from
uninfected mice [13]. A commercially-available Chagas disease
ELISA using recombinant protein is sold by Wiener Laboratories
(Rosario, Argentina); and another ELISA contains three antigens
[14] but in neither case are the identities of the proteins or
peptides published. In contrast, in a recent screen of 400
recombinant proteins from the south American trypanosome,
Trypanosoma cruzi, Cooley et al were able to identify 16 proteins
which, in combination, allowed diagnosis of Chagas disease with
100% sensitivity [15]. A multiplex approach was essential since
patient responses were heterogeneous.
An alternative to looking for antibodies is to test for the presence
of trypanosome proteins. The TrypTECT CIATT consists of latex
particles that are coated with a monoclonal antibody to a
trypanosome antigen identified only as an ‘‘internal protein’’. It
is assumed that the particles are agglutinated if the same antigen is
present in the serum [16]. The TrypTECT CIATT test had only a
3% false-negative rate, and was very specific using controls from
trypanosomiasis-free areas serum [16]. In contrast, there was a
high apparent false-positive rate from endemic areas; since the
positive samples were not tested by PCR the true false-positive rate
is unknown [17].
Sera from Leishmaniasis patients were recently used to look for
diagnostic antigens in complex extracts, using Western blotting or
precipitation followed by mass spectrometry [18,19]. We have
here adopted the same approach of extract screening to look for
antigens that might form the basis of a serological test for T. b.
rhodesiense infection, but have followed up with further tests using
recombinant proteins.
Materials and Methods
Human Serum Samples
Ethical clearance for this study was obtained from the Ministry
of Health and the Uganda National Council for Science and
Technology and from the Ethical review board of the University of
Heidelberg. Samples were collected from 30 sleeping sickness
patients and 30 controls, after written consent, at Namungalwe
treatment centre in collaboration with Uganda National HAT
control program. The conditions of collection conformed to Good
Clinical Practice (GCP) and Good Laboratory Practice (GLP).
Immediately after collecting blood, we spotted approximately
200 ml on FTA cards (Whatmann). At the clinic, sleeping sickness
infection was confirmed by microscopy. In the lab we processed
discs punched from the FTA cards using the FTA purification
reagent as instructed by manufacturer. We then tested for T.
brucei species and subspecies (T. b. rhodesiense SRA gene), using
nested PCR and the primers and conditions described in [20]. The
controls were healthy volunteers with no clinical signs of
trypanosomiasis, malaria or gastrointestinal infection; the absence
of trypanosomes in their blood was confirmed by microscopy.
Plasma/sera were stored in liquid nitrogen before transfer to the
laboratory. Three infection sera were discarded because they had
become degraded during transit: SDS-PAGE of these sera
revealed no detectable protein.
Cell Fractionation
All proteomic studies were done using in vitro cultivated
Trypanosoma brucei brucei, strain Lister 427. Procyclic- and
bloodstream-form trypanosomes (1610
9) were washed in PBS,
freeze-thawed to release VSG, then disrupted by grinding with
silicon carbide [21]. Organelles were sedimented from the post-
nuclear supernatant as described, and the soluble fraction was
retained. The glycosomes were then further purified by sucrose
gradient centrifugation, as previously described [22,23].
Cytoskeletons were prepared as described by [24]. 1610
8
procyclic form T. brucei were harvested by centrifugation at 800 g
for 10 min. Washed parasites were resuspended in PIPES buffer
(100 mM PIPES (pH 6.9), 2 mM EGTA, 0.1 mM EDTA, 1 mM
MgSO4, with 1 tablet of ‘complete EDTA –Free’ protease
inhibitors cocktail (Roche Applied Science, Mannheim, Germany)
per 10 ml). The mixture was centrifuged at 18006g for 10
minutes, then the supernatant and pellet were analysed by gel
electrophoresis.
Western Blot
One-dimensional SDS-PAGE was performed under denaturing
and reducing conditions, transferred onto nitrocellulose mem-
branes (Schleicher & Schu ¨ll, Dassel, Germany), which were
blocked overnight at 4uC with 5% non-fat milk in Tris Buffered
Saline-Tween 20 (TBS-T).
Sera from infected individuals and non-infected controls,
diluted 1:5000 or 1:1000 in 5% milk (TBS-Tween), were added
and incubated for 1 hour at room temperature. After incubation
membranes were washed three times (10 min) with TBS-T, and
anti-human IgG coupled with Horse Radish Peroxidase (GE
Healthcares, UK), diluted 1:5000 in 5% non-fat milk in TBS-T
was added for 1 h. After incubation the membrane was finally
washed three times (10 min) and developed according to the ECL
detection kit manual (Amersham Biosciences, Freiburg, Germany).
2D Electrophoresis
A whole cell extract of procyclic trypanosomes was obtained by
pelleting a total of 2610
8 cells by centrifugation at 2000 rpm for
10 min. Cells were washed with 1 mL 1x PBS and pellet
resuspended in 1 mL 2D sample buffer (7 M Urea, 2 M Thio
Urea 4% CHAPS, 1% DTT and ‘complete EDTA –Free’
Protease Inhibitor cocktail (Roche Applied Science, Mannheim,
Germany)). The suspension was incubated on ice for 15 min and
then centrifuged at 6000 rpm for 5 min to obtain a supernatant.
The protein concentration of the extract was determined by the
Bradford assay. Sample equivalent to 200 mg protein was loaded
on a non-linear immobilized pH gradient IPG strip (3.5–10.0 NL
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50 V for 12 h followed by focusing for a total of 50 kVh at 20oC.
For protein reduction, the IPG strip was shaken at 100 rpm for
15 min in 0.4 mg/mL DTT, 40 mM Tris-HCl (pH 8.8), 7 M
urea, 10% glycerol and 2% (w/v) SDS. Reduced proteins were
alkylated by incubating the IPG strip in fresh buffer with the DTT
replaced by 5 mg/mL iodoacetamide. The IPG strip was then
transferred to the top of a 9–16% polyacrylamide gel (acrylamide/
bisacrylamide 37.5:1, 2.6% cross-linker; gel dimension,
20 cm620 cm61 mm) and held in place with 0.5% (w/v) low-
melt agarose. Electrophoresis in the second dimension was
performed in a Protean II Multicell xi system (Bio-Rad) using
25 mM Tris, 192 mM Glycine, 0.1% SDS buffer at 10uC until the
bromophenol blue dye front was 1 cm from the bottom of the gel.
Thiol groups were subsequently blocked by incubating with
100 ml of a solution containing Tris-HCl (50 mM) pH 6.8, urea
(6 M), glycerol (30% v/v), SDS (2% w/v), iodoacetamide (2.5%
w/v) and a trace of Bromophenol Blue for 5 min. Three parallel 2-
dimensional gels were made. Two were separately subjected to
western blotting by probing with pooled infected and control sera.
The other gel was stained with Coomassie brilliant blue and
antigen spots excised for analysis by mass spectrometry.
Gene Cloning and Expression
Proteins were expressed as His-or glutathione-S-transferase
(GST) fusions, and purified according to standard protocols.
Briefly, the HSP70 (Tb927.7.1030) and PFR1 (Tb927.3.4290-
4330) open reading frames were amplified by PCR, cloned into
pGEMT-easy, then transfer cloned into the pGEX-4T2 expression
vector. Expression of protein was induced by addition of IPTG
and cells were lysed in PBS-0.4M EDTA, 200 mM PMSF, and
‘complete EDTA–free’ protease inhibitor cocktail (Roche Applied
Science, Mannheim, Germany). The proteins were purified on
glutathione-Sepharose and eluted with reduced glutathione. The
open reading frames of histones H3 and H2B were cloned as Bgl
II- Hind III fragments into pQEA. The rhodesian open reading
frame [25] was cloned as a Bam HI- HindD III fragment into
pQE30 or pET28a. We also similarly cloned fragments encoding
100 amino acids of TbNT2 (Tb927.2.6150), TbNT5
(Tb927.2.6240), and TbNT10 (Tb09.160.5480). The fragment -
residues 207–309 for TbNT10 and homologous segments of NT2
and NT5 - is predicted to be extracellular by Bioedit and Protein
Toolbox programs. Expression of the NT2 and NT5 fragments
was too poor for further use. The other His-tagged proteins were
purified by Nickel affinity chromatography (Qiagen).
Results
Immunoblotting of Sub-Cellular Fractions
Our aim was to find a set of trypanosome proteins that are
recognised by sera from patients with African sleeping sickness, but
not by control sera from the same region. Sera were obtained from
T. b. rhodesiense patients who presented at the sleeping sickness
clinic in Namungalwe Health centre, Eastern Uganda, and from
volunteer healthy controls from the same area (see Methods). Two
batches of sera were used: batch 1 (numbered 1–20 in Figures 1A,
1B and 1C and Figure 2A) and, when these were exhausted, batch
2 (numbered above 20, Figure 1D and Figures 2B, 2C).
A variety of different extracts was prepared from cultivated T. b.
brucei, and analysed by western blotting using the sera. For extract
preparation we chose to use a strain of T. b. brucei that grows to
relatively high densities in culture, even as bloodstream forms,
since this is a prerequisite for large-scale cell fractionation and
proteomic analysis. The subspecies difference should not affect the
sensitivity, since T. b. rhodesiense differs from T. b. brucei only by the
presence of a single protein (SRA) [6].
First, we examined a cytosolic fraction from bloodstream
trypanosomes. These blots (Figure 1A) were dominated by a band
of about 60 kDa - perhaps a VSG, since VSGs have molecular
weights in this region. This band was recognised by control and
infection sera. Glycosomes from bloodstream forms, which contain
abundant glycolytic enzymes, were also examined. Very few, faint
bands were seen but there was one extremely faint band of about
37 kDa that appeared to be recognised only by infection sera (not
shown). By aligning the blots with the protein stain, we estimated
that this band could either be phosphoglycerate kinase (PGKC), or
another protein of similar molecular weight.
Using procyclic forms, to eliminate the strong VSG band, we
first examined the cytosolic fraction. The human sera reacted with
many bands, but none was preferentially present in the sleeping
sickness samples (Figure 1B). We also prepared cytoskeletons by
detergent extraction. Using the supernatant (soluble) fraction, two
areas at 70 kDa and 35 kDa gave potentially specific reactivity
(Figure 1C). Both were examined by mass spectrometry. The
70 kDa band was identified as HSP70; we were unable to identify
the 35 kDa protein. The cytoskeleton fraction had a prominent
reactivity below 20 kDa (Figure 1D). This contained predomi-
nantly histone H2B, although the other core histones (H3 and
some H2A and H4) were also detected.
Since the Western blots were yielding predominantly abundant,
highly-conserved proteins, we attempted to increase the sensitivity
using 2D gels. This time, we probed matched Western blots with
pooled infection and control sera. A few spots seemed to be
specific for infection sera (Supplementary Figure S1), so proteins in
the relevant area were identified by mass spectrometry. The only
peptides that could be assigned – apart from HSP70 - came from
abundant mitochondrial proteins. These seemed unlikely to be
useful as diagnostics since they are evolutionarily conserved and
are preferentially expressed by procyclic-form trypanosomes.
In our Western blotting we could only detect immune responses
to denatured proteins. In order to extend out analysis to native
proteins, we cross-linked antibodies from pooled sera (batch 1) to
beads, and immunoprecipitated proteins from procyclic trypano-
some extracts. Procyclic extracts were chosen both to avoid the
abundant VSG, and because of the previously-reported use of
procyclic extract in an agglutination test. We compared the
immunoprecipitates by SDS-PAGE, and detected no differences at
all. We concluded that if any other proteins were specifically
immunoprecipitated by infection sera, the signal was masked by
the background from highly abundant proteins.
Analyses of Recombinant Proteins
Our analyses had yielded four candidate antigens: HSP70,
histone H2B, histone H3, and PGKC. To find out whether any of
these proteins could be a component of a diagnostic, we tested
purified proteins for reactivity with the human sera. Purified
PGKC was available, and we expressed HSP70 as a recombinant
protein, fused to glutathione S transferase (GST), and also made
His-tagged histone H2B and histone H3. In addition, we tested
some other available proteins: paraflagellar rod protein 1 (PFR1-
GST), and His-tagged TbNT10 and rhodesain, chosen either
because they were candidate diagnostics for T. cruzi, or because
they are potentially exposed on the trypanosome surface. The
results suggested that HSP70, but not the other proteins, was
preferentially recognised by the infection sera. (Note that PFR1-
GST was not recognised, ruling out a reaction of the sera with
GST.) Figure 2A shows Western blot results with batch 1 sera, and
Figures 2B and 2C those with batch 2. The complete blots are
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PLoS ONE | www.plosone.org 3 March 2010 | Volume 5 | Issue 3 | e9630Figure 1. Interaction of human sera with trypanosome fractions. Trypanosome extracts were analysed by Western blotting using sera from
sleeping sickness patients (left) or controls (right) diluted at 1:1000. Bands at the positions indicated were analysed by mass spectrometry; the
identified protein is indicated. Serum sample numbers are beneath the lanes and marker positions (kD) are shown to the left. (A) Bloodstream-form
cytosol. (B) Procyclic-form cytosol. (C) Procyclic-form detergent-soluble fraction. (D) Procyclic-form cytoskeleton fraction.
doi:10.1371/journal.pone.0009630.g001
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preparations appeared pure by Coomassie staining, many of the
sera showed background reactivity with contaminating E. coli
proteins. This resulted in high backgrounds in ELISA assays (not
shown). Some sera also consistently gave high background on the
membrane. To measure specific reactivity to TbHSP70, we
Figure 2. Interaction of human sera with recombinant T. brucei HSP70. (A) T. brucei HSP70 was produced in E. coli as a fusion with
glutathione-S-transferase (GST). Panel (A) shows the results using the serum batch 1, and panels (B) and (C) different pairs of Western blots for serum
batch 2. (D) Reactivity of all sera against HSP70. The signal of the HSP70 band was measured, and background from immediately above and below
the band was subtracted. In each experiment, 20 control sera and 20 infection sera were examined, and the average signal was calculated. The result
for each serum was then calculated relative to the average. Each spot represents the average for 3 or 4 Western blots.
doi:10.1371/journal.pone.0009630.g002
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quantitate the results, the batch 2 sera were tested three times,
each time in batches of 10 controls and 10 infected; to normalise
the results for different blots, the 70 kDa signal strengths were
calculated relative to the average signal for all 20 sera in the
experiment. The results are plotted in Figure 2D and details for
each serum in Supplementary Figure S3. The median signal in the
infection sera was 2.4 times higher than that from control sera
(horizontal lines), but due to the large range in reactivity of the
sera, the difference was not statistically significant (Wilcoxon
ranking test). Diagnostic tests usually involve selecting a cut-off of
reactivity: samples above the cut-off are regarded as positive, and
those below it, negative. Using a cut-off of 0.5 relative signal
intensity (dotted line in Figure 2D), the Western blot would have
diagnosed 70% of the sleeping sickness patients, with a false-
positive result for 35% of controls.
Discussion
Our proteomic screen was set up to identify antigenic proteins
present in HAT patient sera, with a focus on T. b. rhodesiense. Our
approach enabled us, in effect, to screen many hundreds of
proteins present in various T. b. brucei subcellular fractions. Our
most important conclusion was that – with the possible exception
of TbHSP70 – none of the T. brucei proteins that we detected by
Coomassie staining was likely to be useful as a diagnostic antigen
for sleeping sickness. (For the 1D-electrophoresis studies, bearing
in mind that some purification was done, a Coomassie detection
limit of about 20 ng [26,27] translates into 0.01% to 0.2% of total
cell protein.) This rules out a large proportion of the recombinant
proteins that have been produced so far, since there has been a
strong focus on abundant metabolic enzymes.
From our initial screening, HSP70, histone H2B, histone H3,
and PGKC were selected for further analysis of cloned and
purified products. In addition we cloned proteins not identified
during the screening, but considered to be potentially antigenic.
TbNTs play a central role in purine salvage due to the inherent
inability of trypanosomes to effect de novo biosynthesis. The first
step in this salvage entails import of purines across the cell
membrane by nucleoside or nucleobase transporters [28]. Due to
their crucial role, we speculated that many of the TbNTs must be
expressed by bloodstream-form T. brucei. Rhodesain was included
in the analysis because its counterpart in T. congolense was shown to
be immunogenic in cattle [29].
No specific reactivity was found for histones H2B and H3,
PGKC, PFR1, rhodesain and TbNT10, but we found that most
sera from sleeping sickness patients reacted with T. brucei HSP70.
Some control sera also reacted: this could be a cross reaction, or
might indicate previous exposure to non infective trypanosomes,
such as T. b. brucei, circulating alongside T. b. rhodesiense within the
tsetse fly and the domestic animal reservoir. Misdiagnosis or the
controls, due to the low sensitivity of the available parasitological
tests, is unlikely since all controls remained non-parasitaemic, with
no signs suggestive of HAT, during follow-up checks. Since our
samples came from only 60 individuals (30 patients and 30
controls), testing with a larger panel of sera will be required to
determine the sensitivity and selectivity of the interaction with
HSP70. In addition, our study did not investigate whether the
presence of other infections (e.g. malaria, Leishmaniasis) would
also result in a positive signal.
Based on the results shown here, we conclude that although
TbHSP70 cannot be used alone to diagnose trypanosomiasis, it
might be a useful component of a multiplex diagnostic containing
several immunogenic proteins. Results with T. cruzi and diagnos-
tics have similarly suggested that several antigens are required.
The antigen panel chosen by Cooley et al. [15] was biased by
design towards abundant proteins, and the final list included
mitochondrial HSP70, a ribosomal protein, a paraflagellar rod
protein and two other flagellar proteins, as well as glycosomal
phosphoenol pyruvate carboxykinase. A different T. cruzi study
detected antibodies to HSP70 in chronically-infected Chagas
patients [30]. Leishmania proteomics studies also identified
abundant proteins: HSP70, another chaperone (Grp78), a surface
protease and translation factors [18,19]; one of the studies also
found several glycosomal proteins. The potential of these
Leishmania proteins as diagnostics was however not confirmed
using pure protein.
The approach undertaken in this study had clear limitations.
Bands or spots were chosen by Western blotting, then proteins
with equivalent migration were identified from another gel. If a
signal is seen on a blot, it could arise from any protein migrating at
that position, but mass spectrometry detects only the most
abundant ones, which may not react with the sera at all. Similarly,
our immunoprecipitation experiments were limited to procyclic-
form extracts. We therefore suggest that more thorough
purification of different fractions, taken from both bloodstream
and procyclic forms, and followed by quantitative mass spectrom-
etry, will be required to identify good diagnostic antigens for T. b.
rhodesiense infection.
Supporting Information
Figure S1 2-dimensional gel electrophoresis and Western
blotting. Extracts were separated by isoelectric focussing (pH
shown above the gel and blots) then by size (size markers on the
right). Duplicate Western blots were probed with pooled infection
(A) or control (B) sera (sera 1–20) and compared. Areas containing
proteins that reacted specifically with infection sera were excised
from a Coomassie-stained gel (C) and identified by mass
spectrometry. Proteins identified were: 1, 4, 5 - HSP70 2 -
Tb927.8.6170 - transketolase 6 - Tb927.6.2790 - threonine
dehydrogenase 7 - Tb11.01.5860 - HSP60 family The proteins
identified for 2, 6 and 7 are specific to procyclics so are not good
diagnostic candidates. The patchy background on the blots was see
in two independent experiments, so is presumably a characteristic
of the sera.
Found at: doi:10.1371/journal.pone.0009630.s001 (3.47 MB EPS)
Figure S2 Reactions of sera with purified T. brucei HSP70: whole
Western blots. T. brucei HSP70 was produced in E. coli as a fusion
with glutathione-S-transferase (GST). Purified protein (H) is shown
next to the marker on a Coomassie-stained gel, and Western blot
strips stained using infection sera diluted to 1:1000. (A) Blot shown
in Figure 2A. (B) Upper blots shown in Figure 2B, run and
detected together. (C) Lower blots shown in Figure 2B, run and
detected together. A typical Coomassie stain of the purified protein
is shown to the left of Figure 2B. Note the cross-reaction with E.
coli proteins which cannot be seen on the Coomassie stain. This
background precluded the use of ELISA to quantitate reactivity
with HSP70. Also, some sera consistently gave dark backgrounds
on the membranes. Sera 32, 55 and 107 were checked by SDS-
PAGE and found to contain no protein, so results with these were
discarded.
Found at: doi:10.1371/journal.pone.0009630.s002 (2.88 MB EPS)
Figure S3 Details of the reactivity of human sera (batch 2) with
T. brucei HSP70. Results are arithmetic mean and standard
deviation for 3 or 4 experiments.
Found at: doi:10.1371/journal.pone.0009630.s003 (0.44 MB EPS)
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